SB 432 expands probation eligibility for certain major controlled substances offenses (excluding heroin, fentanyl, carfentanil, and their derivatives) that were previously ineligible under Michigan law. It allows courts to delay sentencing for up to one year to enable defendants to participate in drug treatment programs, requiring the court to document the reason for the delay in writing. The bill establishes a monthly supervision fee of $30 (without electronic monitoring) or $60 (with monitoring), capped at 12 months, which can be paid in installments or waived for indigent individuals. This applies to adult defendants not subject to juvenile probation.
HB 5259 establishes a peer mentorship program within Michigan's Department of Military and Veterans Affairs to connect active-duty military members (including National Guard and reserves) and veterans with volunteer mentors. The program helps participants access resources for education, employment, family issues, financial matters, and health care - including mental health and substance use disorder support through veteran navigators. Mentors must be recruited from veterans where possible, and program records are protected from public disclosure under Michigan's freedom of information law. The bill requires companion legislation (HB 5270) to take effect.
HB 4417 requires Michigan's state department to provide opioid antagonists (like naloxone) at no cost to life support agencies - such as ambulance services - when requested. This directly affects emergency medical services (EMS) providers operating life support vehicles, ensuring these vehicles are equipped to respond to opioid overdoses. The bill amends Michigan's Public Health Code to mandate this free distribution, streamlining access for first responders. It focuses on concrete policy change: making overdose-reversal medications readily available in emergency vehicles without cost to EMS agencies.
SB 398 modifies requirements for substance use disorder treatment programs in Michigan and prohibits state agencies from creating new rules about these services. It directly affects treatment providers and the state health department (DHHS) by changing existing standards for program operations and blocking future rulemaking on specific service requirements. Key provisions include updating program eligibility rules under MCL 333.6230 and banning the development of new rules under MCL 333.6234. The bill aims to streamline program standards while preventing additional regulatory burdens on treatment providers.
HB 4428 allows individuals and governmental entities receiving free opioid overdose reversal medications (opioid antagonists) from the Department of Health and Human Services (DHHS) to choose the specific type, dose, or delivery method of the medication. This provision applies when the DHHS distributes these medications to help reduce opioid-related overdoses across the state. The choice is intended to help recipients better address local needs. However, recipients cannot choose a specific formulation or dosage if doing so would jeopardize federal funding for the DHHS.
HB 4684 requires Michigan health insurers to create and submit a plan ensuring coverage for a broad range of pain management services, including nonopioid medications and nonmedication alternatives to opioids. The plan must be filed with the state insurance department for approval, which will review whether the plan adequately covers alternatives to opioids without unduly favoring opioid prescriptions. Insurers must also distribute educational materials to network providers and post the plan on their public website. This bill directly affects all health insurers operating in Michigan who issue, deliver, or renew health insurance policies in the state.
SB 222 expands who can petition for continued involuntary mental health treatment under Michigan's assisted outpatient program. It adds psychiatric nurse practitioners and physician assistants (working under a psychiatrist's delegation) to the list of eligible petitioners and allows individuals aged 18 or older to file petitions for themselves. Petitions must include a clinical certificate and evidence of a psychiatrist's consultation (unless the filer is a psychiatrist), along with details about the treatment program and estimated duration needed. This change directly affects patients requiring ongoing treatment and increases the number of authorized mental health providers who can initiate the petition process.
SB 404 requires public schools in Michigan to ensure at least one staff member at each school is trained to administer naloxone (an opioid overdose reversal medication) if the state health department provides it at no cost. Schools must develop policies requiring staff to notify parents when naloxone is used and call 9-1-1 for suspected opioid overdoses. The bill directly affects public school districts, intermediate districts, and public school academies by mandating training and response protocols for opioid-related emergencies. It specifies naloxone must be FDA-approved and defines "opioid-related overdose" to include symptoms like respiratory depression or unconsciousness needing medical help.
SB 405 amends Michigan's "Administration of Opioid Antagonists Act" by revising the definition of "governmental agency" to explicitly exclude school district boards, public school academies, and licensed healthcare providers (under Public Health Code Part 209). This change means these entities will no longer be subject to the act's requirements regarding opioid antagonist access and training. The bill directly affects school districts, public school academies, and licensed healthcare facilities by removing them from the scope of the law. The amendment clarifies which organizations must comply with the act's provisions, focusing on state and local government entities rather than schools or healthcare providers. This is a technical definitional update with no new requirements or funding changes.
SB 629 creates a legal framework for needle and syringe access programs in Michigan to reduce the spread of communicable diseases like HIV and hepatitis. It allows authorized programs (run by health departments or local agencies) to distribute sterile needles/syringes and provide related services. Participants in these programs are exempt from criminal penalties under existing laws for possessing needles, trace amounts of drugs in used equipment, or drug testing supplies. The bill directly affects people who use injection drugs, local health programs, and law enforcement by clarifying that program participation does not violate drug possession or paraphernalia laws.
